Introduction {#Sec1}
============

Lowering intraocular pressure (IOP) is the only evidence-based strategy for managing patients with glaucoma and prostaglandin analogs (PGAs) that effectively lower IOP represent the current first-line topical ophthalmic treatment for the disease \[[@CR1]\]. However, visual field defects associated with glaucoma can continue to progress even after IOP is lowered to a specific target level \[[@CR2]\]. Nearly, 40% of patients who have experienced a significant IOP reduction with PGA therapy require a further reduction and start to receive an additional topical ophthalmic medication \[[@CR3], [@CR4]\]. Combination regimens using multiple different ophthalmic solutions are less convenient for patients and increase their burden because patients need to take their prescribed ophthalmic solutions several times a day with a wait of at least 5 min between taking different solutions \[[@CR5]--[@CR7]\]. In contrast, fixed drugs of a PGA and a β-blocker produce a similar additive IOP-lowering effect without increasing the burden on patients and thus may be advantageous in preventing the risk of becoming non-adherent after the addition of a second drug \[[@CR8]\].

Previous studies have reported significant IOP reductions after switching from PGA monotherapy (latanoprost, travoprost, or bimatoprost) to fixed drugs containing the corresponding PGA \[[@CR9]--[@CR11]\]. However, these studies mainly included patients with open-angle glaucoma with a high baseline IOP (\>19 mmHg) or those with ocular hypertension (OH). No studies have evaluated the efficacy of travoprost/timolol fixed combination (Duotrav^®^, Alcon Laboratories, Inc., Fort Worth, TX, USA) therapy in patients whose IOP has already been lowered to ≤19 mmHg with PGA monotherapy \[[@CR10], [@CR12], [@CR13]\].

Because visual field defects progress steadily even in normal tension glaucoma (NTG) \[[@CR14]\], a condition where IOP remains normal, NTG patients are also treated with PGA-based IOP-lowering therapy \[[@CR15], [@CR16]\], and if visual field defects continue to progress despite a significant IOP reduction with initial monotherapy, a second drug is added \[[@CR17]\]. Thus, these patients are also potential candidates to receive fixed drugs therapy. However, the efficacy of switching to a fixed drug therapy has not been extensively studied in this patient population.

The four PGAs currently available for the treatment of glaucoma are travoprost, latanoprost, tafluprost, and bimatoprost and for each of these, fixed combination ophthalmic solutions are commercially available or have been approved \[[@CR18]\]. Among these solutions, Duotrav which contains polyquaternium-1 (Polyquad^®^, Alcon Laboratories, Inc., Fort Worth, TX, USA) as a preservative is the only one that does not contain benzalkonium chloride (BAK), a preservative that increases the risk of corneal damage \[[@CR19]\], when switching from monotherapy.

In the present study, we investigated whether patients with open-angle glaucoma, including NTG, or with OH who had been treated with one of the four PGAs for at least 3 months and some of whom had an IOP of less than 19 mmHg would experience a further reduction in IOP after switching to Duotrav. Here, we report the efficacy of Duotrav in this patient population as well as the local and systemic safety results, including effects on the ocular surface.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Patients eligible for the study were aged 20 years or older, had been diagnosed with primary open-angle glaucoma (POAG), NTG, or OH, and were judged by their treating doctors to require additional ophthalmic medication due to the progression of visual field defects or uncontrolled IOP despite continued treatment with one of four PGAs for at least 3 months.

Exclusion criteria: (1) a mean deviation (MD) of less than −20 dB by visual field testing; (2) a history of hypersensitivity to β-blockers or a contraindication to β-blockers (e.g., bronchial asthma and uncontrolled heart failure); (3) the presence of chronic or recurrent uveitis, scleritis or corneal herpes; (4) a history of ocular trauma, intraocular surgery or laser treatment within 3 months prior to the baseline evaluation; (5) any condition that would preclude accurate IOP measurement by applanation tonometry; (6) the use of ophthalmic corticosteroids; (7) serious ocular complications; (8) pregnancy or lactation; and (9) severe dementia. Patients whose participation in the study was deemed inappropriate by their treating doctors were also excluded. Gender and the presence of dry eyes were not considered when enrolling patients.

Prior to any study procedures, the protocol and all aspects of the study were reviewed and approved by the ethics committee of Kitamachi Clinic, Tohoku University Hospital, Juntendo University Urayasu Hospital, the Jikei University School of Medicine, Nakano General Hospital, Fussa Hospital, Fukui-ken Saiseikai Hospital and Minami-Matsuyama Hospital. This study was registered with the University Hospital Medical Information Network (UMIN), number UMIN000007028.

Among potential subjects who met all of the inclusion and none of the exclusion criteria, only those who signed informed consent forms through the process according to the principles of the Helsinki declaration were enrolled in the study.

Procedures {#Sec4}
----------

This was a prospective multicenter open-label study. Patients requiring a further IOP reduction in the opinion of their treating doctors were switched from PGA monotherapy to travoprost/timolol maleate fixed combination (Duotrav) without having a period of washout from the previous PGA. One drop of Duotrav was instilled into the conjunctival sac of one or both eyes in the morning once daily. Patients underwent protocol-specified examinations before (at baseline) and at 4, 8, and 12 weeks after switching. In each patient, IOP was measured in duplicate by the same examiner throughout the study period using the Goldmann applanation tonometer and the mean of the two values was used for data analysis. IOP measurements during follow-up were performed at the same time of day (±2 h) as baseline measurements. During each visit, eyes were examined for superficial punctate keratopathy (SPK) and conjunctival hyperemia by slit-lamp microscopy. The degree of SPK was scored on a 5-point scale from 0 to 4 according to the cornea diagram of the National Eye Institute (NEI) classification system \[[@CR20]\]. The degree of conjunctival hyperemia was scored on a 4-point scale, where 0 = no dilated vessels, 1 = dilation of primarily small vessels, 2 = dilation of small and large vessels, and 3 = significant dilation of small and large vessels. These assessments were rated by reference to sample pictures of eyes with SPK and conjunctival hyperemia that were provided beforehand. To collect data on adverse events, doctors asked patients if they had any symptoms and also examined them for any signs or symptoms during each visit. Patients were always asked whether there was irritation, foreign body sensations, dry feeling or itching in the patient's eyes. Examination for eyelash changes, blepharal pigmentation and deepening of the eyelid sulcus was also mandatory. To detect these adverse events, pictures of eyes were taken every visit and changes from baseline were recorded. Examinations were performed according to each center's practice and instruments, and conditions for taking pictures were not standardized. At the start of Duotrav therapy, patients were instructed to remove any solution spilled on the eyelid skin by wiping or washing their face. At the start and end of the study, systolic/diastolic blood pressure and pulse rate were measured.

Statistical Analysis {#Sec5}
--------------------

Primary endpoint was IOP, IOP reduction and IOP reduction rate from baseline. Secondary endpoint was safety including the score of SPK and conjunctival hyperemia.

Patient data including disease subtype and IOP measurements were collected at each center were sent to and assembled by Tajimi Iwase Eye Clinic in an anonymous form. An ophthalmologist not involved in data collection (M.S.) validated each case. Patients who completed at least 4 weeks of follow-up were included in the analysis.

Baseline IOP was defined as the mean of two measurements obtained at two visits during PGA monotherapy. If both eyes were eligible for the study, the eye with a higher baseline IOP was chose or, if both eyes had an equal baseline IOP, the right eye was selected as the study eye. Absolute and percent IOP reductions from baseline were analyzed for study eyes of patients who were followed up for at least 4 weeks after starting Duotrav therapy using repeated-measures analysis of variance and Steel's multiple comparison test. SPK and conjunctival hyperemia scores were analyzed by Steel's test. Missing values after 4 weeks were imputed using last observation carried forward method.

Adverse events for which a relationship to Duotrav could not be ruled out were graded according to the following criteria: mild (the patient recognized the adverse event but could tolerate the symptom), moderate (the patient found the symptom interfered with normal activities and was uncomfortable) and severe (the symptom was physically disabling and prevented the patient from working and normal activities). Eyelash changes, blepharal pigmentation and deepening of the eyelid sulcus were analyzed separately and cumulative incidence rates were calculated. Overall incidence rate of adverse events was also calculated. Changes from baseline in blood pressure, pulse rate were analyzed using the Kruskal--Wallis test. Statistical analysis was performed by QOL RD Co., Ltd., and SOC Co., Ltd., using JMP^®^9.0 and SAS^®^9.3 (SAS Institute Inc., Cary, NC, USA) with a two-sided significance level of 5%.

Results {#Sec6}
=======

The study was conducted from August 2011 to March 2013. Among 166 patients who gave informed consent for the study, 162 patients (97.6%) were eligible according to the inclusion and exclusion criteria. Five of these 162 patients dropped out within 4 weeks (one developed eye pruritus, two requested treatment discontinuation and two missed visits); the remaining 157 patients (96.9%) with at least 4 weeks of follow-up were included in the analysis.

The analysis population consisted of 54 males and 103 females with a mean age of 66.6 ± 11.3 years (range 39--88 years). Of these, 60 (38.2%) had POAG, 78 (49.7%) had NTG, and 19 (12.1%) had OH. There were no significant differences in age or sex between the disease subgroups (Table [1](#Tab1){ref-type="table"}). Ten of 157 patients (6.4%) discontinued the study before 12 weeks. Reasons for discontinuation included blurred vision (1), increased blood pressure and rash (1), deepening of the eyelid sulcus and blepharoptosis (1), eye irritation (1), insufficient IOP-lowering effect (1), patient's request (4), and loss to follow-up (1).Table 1Patient characteristicsCharacteristicPOAGOHNTGTotal*n*601978157Male, *n* (%)14 (24.6%)4 (21.1%)34 (43.6%)54Female, *n* (%)43 (75.4%)15 (78.9%)44 (56.4%)103Age, years*n* = 60*n* = 19*n* = 78*n* = 15767.5 ± 11.8 (39--88)68.2 ± 10.8 (47--87)65.5 ± 11.2 (40--88)66.6 ± 11.3 (39--88)Previous PGA, *n* (%) Travoprost2383970 (44.6%) Latanoprost1552545 (28.7%) Tafluprost164929 (18.5%) Bimatoprost62513 (8.3%)Baseline IOP, mmHg*n* = 60*n* = 19*n* = 78*n* = 15717.9 ± 2.7 (12.0--27.5)18.8 ± 2.9 (13.5--22.5)14.5 ± 2.2 (9.5--19.5)16.3 ± 3.1 (9.5--27.5)Corneal thickness, μm*n* = 37*n* = 7*n* = 65*n* = 109522.4 ± 35.3 (434--629)542.7 ± 40.0 (486--589)524.7 ± 33.1 (454--590)525.0 ± 34.3 (434--629)MD, dB*n* = 57*n* = 19*n* = 73*n* = 149−5.51 ± 4.95 (−19.49--1.09)0.09 ± 1.58 (−2.92--2.54)−5.52 ± 4.77 (−16.06--0.72)−4.80 ± 4.92 (−19.49--2.54)PSD, dB*n* = 57*n* = 19*n* = 73*n* = 1496.63 ± 4.30 (1.15--14.93)2.36 ± 1.59 (1.15--6.81)7.12 ± 4.46 (1.25--16.68)6.33 ± 4.40 (1.15--16.68)Data are shown as mean ± standard deviation (range) unless otherwise stated*OH* ocular hypertension, *IOP* intraocular pressure, *MD* mean deviation, *NTG* normal tension glaucoma, *PGA* prostaglandin analog, *POAG* primary open-angle glaucoma, *PSD* pattern standard deviation

After the initiation of travoprost/timolol maleate fixed combination (Duotrav) treatment, the mean IOP of eyes included in the analysis significantly decreased from 16.3 ± 3.1 mmHg at baseline to 14.6 ± 3.1 mmHg at 4 weeks, 14.7 ± 3.3 mmHg at 8 weeks and 14.6 ± 3.2 mmHg at 12 weeks (*P* \< 0.0001 for all time points). The mean percent reduction in IOP from baseline was 10.3 ± 12.7%, 9.4 ± 14.3%, and 10.1 ± 13.0% at 4, 8, and 12 weeks, respectively.

Individual baseline IOP values had a wide range from 9.5 to 27.5 mmHg (interquartile range 14.5 to 18.5 mmHg) and were ≥19 mmHg for 33 eyes (21.0%), ≥15 to \<19 mmHg for 78 eyes (49.7%), and \<15 mmHg for 46 eyes (29.3%; Fig. [1](#Fig1){ref-type="fig"}). We then assessed the treatment effect by baseline IOP. When study eyes were divided into three groups according to baseline IOP (≥19 mmHg, ≥15 to \<19 mmHg, or \<15 mmHg), all groups had significant IOP reductions from baseline at 4, 8, and 12 weeks after switching to Duotrav (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Distribution of baseline intraocular pressureFig. 2Intraocular pressure reductions after switching by baseline intraocular pressure subgroups. *Asterisks* repeated-measures analysis of variance and Steel's multiple comparison test. *IOP* intraocular pressure, *SD* standard deviation

In a multiple regression analysis with IOP reduction from baseline at 12 weeks after switching to Duotrav as a dependent variable and demographic and baseline characteristics (type of prior PGA, age, gender, treatment duration, baseline IOP, MD and pattern standard deviation (PSD) values as independent variables, the type of PGA used in prior treatment and baseline IOP had a significant association (Table [2](#Tab2){ref-type="table"}).Table 2Multiple regression analysisFactorDegree of freedomSum of squares*F* value*P* valuePGAs3106.70657898.26\<0.0001Age11.13262130.260.6089Sex15.99413391.390.2402Dosing period of PGAs10.00181240.000.9837Baseline intraocular pressure168.917078016.000.0001Baseline MD value16.86354841.590.2090Baseline PSD value111.71280122.720.1014*MD* mean deviation, *PGAs* prostaglandin analogs, *PSD* pattern standard deviationIn a multiple regression analysis with IOP reduction from baseline at 12 weeks after switching to Duotrav as a dependent variable, and demographic and baseline characteristics as independent variables, the type of PGA used in prior treatment and baseline IOP had a significant association. Coefficient of determination \[*R* ^2^\] was 0.29

There was no significant worsening of SPK total scores or conjunctival hyperemia scores after switching to Duotrav (Table [3](#Tab3){ref-type="table"}). During the study, 26 of 166 patients (15.7%) experienced 42 adverse events for which a relationship to Duotrav could not be ruled out. Among the 42 adverse events, 38 in 24 patients were mild in severity. The remaining four events in four patients were graded as moderate and included blepharal pigmentation, eye pruritus, eye irritation, and increased blood pressure. Blepharal pigmentation was reported during the 4-week visit together with skin itching and Duotrav was discontinued at the patient's request. Eye pruritus and eye irritation occurred at 4 and 14 days of treatment, respectively, and increased blood pressure was noted during the 4-week visit together with mild rash. In these three cases, treatment was discontinued at the doctor's discretion and all the events improved or resolved during the study period. Among the mild events observed, increased blurred vision (occurring at 8 weeks in one patient) and deepening of the eyelid sulcus and blepharoptosis (occurring at 17 days in one patient) led to treatment discontinuation at the doctor's discretion (Table [4](#Tab4){ref-type="table"}).Table 3Changes in scores of SPK and conjunctival hyperemia over timeScaleBaseline4 weeks8 weeks12 weeksSPK total scores0.58 ± 1.310.90 ± 1.680.88 ± 1.780.92 ± 1.76*P* value\* vs. baseline--0.12590.16160.1819Conjunctival hyperemia scores0.41 ± 0.640.52 ± 0.690.45 ± 0.610.49 ± 0.63*P* value\* vs. baseline--0.34700.82150.3774Data are shown as mean ± standard deviation*SPK* Superficial punctate keratopathy\* Steel's testTable 4Adverse eventsAdverse eventsMildModerateTotalPatients included in safety analysis166166166Number of events (number of cases)38 (22)4 (4)42 (26)Type*n*%*n*%*n*%Eye disorders34--3--37-- Eye lid sulcus deepened84.884.8 Growth of eyelashes5353 Blepharal pigmentation31.810.642.4 Superficial punctate keratopathy42.442.4 Dry eyes31.831.8 Foreign body sensation in eyes21.221.2 Eyelid ptosis10.610.6 Eye irritation10.610.621.2 Eye pruritus10.610.621.2 Iritis10.610.6 Keratitis10.610.6 Vision blurred10.610.6 Visual acuity reduced10.610.6 Conjunctival hyperemia10.610.6 Corneal epitheliopathy10.610.6Other4--1--5-- Blood pressure increased10.610.6 Headache10.610.6 Herpes zoster10.610.6 Itchy skin10.610.6 Rash10.610.6

All 157 eyes with at least 4 weeks of follow-up underwent serial examinations for eyelash changes, blepharal pigmentation, and deepening of the eyelid sulcus, where a change from baseline was considered an adverse event. The cumulative incidence was highest for eyelash changes (42 patients; 26.8%), followed by blepharal pigmentation (29; 18.5%) and deepening of the eyelid sulcus (13; 8.3%; Table [5](#Tab5){ref-type="table"}).Table 5Cumulative incidence rates of eyelash changes, blepharal pigmentation, and deepening of the eyelid sulcusAdverse event4 weeks8 weeks12 weeksEyelash change, *n* (%)21 (13.4%)30 (19.1%)42 (26.8%)Blepharal pigmentation, *n* (%)19 (12.1%)26 (16.6%)29 (18.5%)Deeping of the eyelid sulcus, *n* (%)7 (4.5%)9 (5.7%)13 (8.3%)

At 12 weeks, there were no significant changes from baseline in the mean systolic blood pressure (135.3 ± 17.4 mmHg at baseline and 132.4 ± 17.5 mmHg at 12 weeks; *P* = 0.4859), diastolic blood pressure (80.2 ± 11.1 and 78.4 ± 10.8 mmHg; *P* = 0.5266) or pulse rate (70.8 ± 13.0 and 68.2 ± 12.1 bpm; *P* = 0.3033) among 151 patients with available data.

Discussion {#Sec7}
==========

In patients with POAG, NTG, or OH whose IOP had been lowered with PGA monotherapy but who were judged to require an additional ophthalmic medication, switching to travoprost/timolol maleate fixed combination (Duotrav) produced a further reduction in IOP after 12 weeks of treatment and was not associated with serious adverse events.

The goal of treating glaucoma is to maintain visual function. Currently, IOP-lowering therapy is the only evidence-based treatment and to prevent the progression of visual field defects, a greater IOP-lowering effect is needed \[[@CR21], [@CR22]\].

Among current topical ophthalmic medications used for the treatment of glaucoma, PGAs are the most effective in lowering IOP and are regarded as the first-line treatment of choice. If the IOP reduction achieved with first-line monotherapy is insufficient, combination therapy using multiple drugs is indicated \[[@CR3], [@CR4]\] and in such cases, fixed drug may be more advantageous for continuous treatment as they cause less events that might lead to early discontinuation \[[@CR5]--[@CR7]\]. Although previous studies reported reductions in IOP after switching from PGA monotherapy to fixed drug containing the corresponding PGA, few studies have evaluated the efficacy of switching from any PGA monotherapy to a specific fixed drug. Among fixed drugs currently available, only Duotrav contains polyquaternium-1 (Polyquad) as a preservative instead of BAK and therefore patients are not exposed to the compound. These considerations led us to design a study to evaluate the efficacy and safety of switching to Duotrav in patients maintained on monotherapy with one of the four PGAs currently available in Japan (travoprost, latanoprost, tafluprost, and bimatoprost).

In the present study, patients had a mean IOP of 16.3 ± 3.1 mmHg at baseline, which was calculated from measurements at two visits during PGA monotherapy. It is not surprising that the IOP before adding a second drug was within the normal range \[[@CR17]\] because NTG is dominant in Japan \[[@CR23]\]. After switching to Duotrav, IOP significantly decreased from baseline at all specified timepoints during the 12-week follow-up period (4, 8, and 12 weeks) with the mean IOP decreasing to 14.6 ± 3.2 mmHg at 12 weeks. This corresponded to a mean 10.1% reduction from the baseline value. PGA therapy reduced IOP by more than 20% from pretreatment values even in patients with NTG \[[@CR24], [@CR25]\]. The 10% reduction observed in this study after switching to Duotrav is similar to those reported previously in NTG populations \[[@CR26], [@CR27]\]. The absolute reduction of about 1.5 mmHg associated with switching to Duotrav seems to represent a meaningful treatment benefit, considering the findings from the Early Manifest Glaucoma Trial where every 1 mmHg of IOP reduction has patient benefit \[[@CR21]\].

Because individual baseline IOP values showed a wide variation, we assessed the treatment effect using baseline IOP values. When study eyes were divided into three groups according to the baseline IOP (≥19 mmHg, ≥15 to \<19 mmHg, or \<15 mmHg), all groups had significant IOP reductions from baseline at 4, 8, and 12 weeks after switching to Duotrav. Previous studies evaluating the efficacy of switching to fixed drug therapy were conducted primarily in eyes with a baseline IOP of ≥20 mmHg or in those with ≥19 mmHg for studies of Duotrav \[[@CR10], [@CR12], [@CR13]\]. In the present study, significant IOP reductions were observed in eyes with a baseline IOP of \<19 mmHg and even in those with \<15 mmHg, suggesting that NTG patients with normal IOP who experience a progression of visual field defects despite PGA monotherapy might also be good candidates for Duotrav therapy.

During the study, close monitoring was performed for SPK and conjunctival hyperemia, the most common side effects of PGA-containing ophthalmic treatments. Side effects were scored according to the NEI classification system and with reference to sample pictures. After the initiation of Duotrav therapy, SPK and conjunctival hyperemia scores showed no significant worsening over time. Based on these results, the effects of Duotrav on the ocular surface were considered minimal in the present study population, including dry eyes. SPK has been reported at a higher frequency in patients using timolol ophthalmic solution \[[@CR28], [@CR29]\] and might be caused by the presence of BAK in the timolol solution \[[@CR30], [@CR31]\]. This preservative has strong antimicrobial activity but adversely affects the ocular surface \[[@CR32], [@CR33]\]. Adverse effects on the ocular surface may therefore be reduced by choosing a BAK-free regimen \[[@CR20], [@CR34]\]. Duotrav is a fixed-combination ophthalmic solution of travoprost and timolol and free of BAK, whereas combination regimens using separate ophthalmic solutions of travoprost and timolol or using other fixed drugs are associated with exposure to BAK because except for travoprost, they all contain BAK. Duotrav contains polyquaternium-1 an alternative that is less toxic to the cornea than BAK \[[@CR35]\]. There have been few studies on the effects of polyquaternium-1 in clinical practice but the present study suggests the advantage of using this compound as a preservative.

No serious adverse events were reported during Duotrav therapy but adverse events in six patients led to treatment discontinuation either at the patient's request or at the doctor's discretion, clearly suggesting that individual patients should be closely monitored. The cumulative incidence of eyelash changes, blepharal pigmentation and deepening of the eyelid sulcus increased throughout the study period. This suggests that it is important to instruct patients to remove any solution spilled on the eyelid skin by wiping or washing their face after the administration of Duotrav. There were no significant changes from baseline in the mean blood pressure or pulse rate after treatment did not change significantly.

This study had some limitations. The number of cases analyzed was relatively small, especially when the cases were divided into three groups, and using a larger number of patients would increase the statistical power. However, the results observed in this study showed a significant reduction of IOP. The open label and no control design might also introduce unconscious bias into some of the findings. The lack of washout phase before switching to Duotrav may be considered another limitation of this study. Therefore, we analyzed the IOP reduction from baseline at 12 weeks using multiple regression analysis and previous treatment was likely to be completely washed out at 12 weeks.

Conclusions {#Sec8}
===========

Duotrav appears to be a useful treatment as it exhibited a good IOP-lowering effect regardless of pretreatment IOP, and was associated with few adverse events. However, a multiple regression analysis identified baseline IOP and the type of PGA used in prior treatment as significant predictors of the magnitude of IOP reduction. This indicates that the magnitude of the effect of Duotrav is influenced by the pretreatment IOP; however, further analysis is required to determine the effect of PGA type. In the second report of this study, we will describe the analysis of our data by prior PGA monotherapy.
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